RSV hospitalizes thousands of people in the US every year. Three new vaccines could help stem the spread, but there are ...

Emmetrope Ophthalmics, LLC ("Emmecell"), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of serious eye diseases, today ...

VisionVentionstm, a pioneering ophthalmic device company, has launched its operations with a commitment to addressing niche, unmet needs in ophthalmic surgery. The company is set to transform the ...

When to get it: RSV vaccines are available at any time, but the CDC says the best time to get one is in late summer and early fall. The efficacy: In clinical trials, Arexvy and Abrysvo were 78% ...

“Adding AIO-001, a potentially best-in-class medicine targeting the ... respiratory syncytial virus vaccine Arexvy, which GSK thinks can reach around $4 billion in annual sales.

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK's proprietary AS01E adjuvant.

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...